دورية أكاديمية
A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101)
| العنوان: | A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101) |
|---|---|
| المؤلفون: | Takashina, Taichi, Asahina, Hajime, Oizumi, Satoshi, Yamada, Noriyuki, Harada, Masao, Takamura, Kei, Yokouchi, Hiroshi, Harada, Toshiyuki, Honjo, Osamu, Ogi, Takahiro, Morikawa, Naoto, Kinoshita, Ichiro, Honda, Ryoichi, Nakano, Kosuke, Kanazawa, Kenya, Amano, Toraji, Dosaka-Akita, Hirotoshi, Isobe, Hiroshi, Nishimura, Masaharu |
| بيانات النشر: | Springer |
| المجموعة: | Hokkaido University Collection of Scholarly and Academic Papers (HUSCAP) / 北海道大学学術成果コレクション |
| مصطلحات موضوعية: | Maintenance therapy, Pemetrexed, Bevacizumab, Erlotinib, Non-small cell lung cancer |
| الوقت: | 490 |
| الوصف: | Background: This study evaluated the efficacy and safety of switch maintenance erlotinib and bevacizumab after induction therapy with carboplatin/pemetrexed/bevacizumab for non-squamous non-small cell lung cancer (NSCLC) with wild-type EGFR. Methods: Enrolled patients had treatment-naive, advanced non-squamous NSCLC with wild-type EGFR. Carboplatin [area under the curve (AUC) 5.0], pemetrexed (500 mg/m2) and bevacizumab (15 mg/kg) were administered on day 1 every 3 weeks for 4-6 cycles. Maintenance therapy with erlotinib (150 mg/body) on day 1 through 21 plus bevacizumab on day 1 every 3 weeks was continued until disease progression or unacceptable toxicity. The primary endpoint was 6-month progression-free survival (PFS); secondary endpoints included overall survival (OS), overall response rate (ORR), toxicity, and quality of life (QOL). Results: Fifty-one patients were enrolled between September 2011 and June 2014. The median number of cycles for induction and maintenance therapy was 4 (range 1-6) and 4 (range 1-20). Twenty-nine patients (58%) received maintenance therapy. The 6-month PFS rate was 59.5% [95% confidence interval (CI) 45.0-72.6%]. The ORR was 48.0% (95% CI 34.8-61.5%), and disease control rate was 86.0% (95% CI 73.8-93.0%). The median PFS and OS were 6.5 months (95% CI 5.8-7.2 months) and 21.4 months (95% CI 15.9-26.9 months), respectively. Although grades ≥ 3 adverse events were observed in 33 patients (66.0%), most were hematologic; there was no febrile neutropenia. QOL was maintained throughout treatment. Conclusions: Carboplatin/pemetrexed/bevacizumab followed by erlotinib and bevacizumab maintenance showed modest efficacy and was well tolerated in non-squamous NSCLC patients with wild-type EGFR. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | http://hdl.handle.net/2115/74964Test; International journal of clinical oncology, 23(6): 1060-1069; http://dx.doi.org/10.1007/s10147-018-1318-zTest |
| DOI: | 10.1007/s10147-018-1318-z |
| الإتاحة: | https://doi.org/10.1007/s10147-018-1318-zTest http://hdl.handle.net/2115/74964Test |
| حقوق: | This is a post-peer-review, pre-copyedit version of an article published in International Journal of Clinical Oncology. The final authenticated version is available online at: http://dx.doi.org/10.1007/s10147-018-1318-zTest |
| رقم الانضمام: | edsbas.27E104A8 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1007/s10147-018-1318-z |
|---|